Bone marrow vascular niche and the control of angiogenesis in multiple myeloma

Frontiers in Bioscience - Landmark

Volumn 19, Issue 2, 2014, Pages 304-311

  Ribatti, Domenico ^a,b   Basile, Antonio ^a   Ruggieri, Simona ^a,b   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Angiogenesis; Multiple myeloma; Review; Tumor progression; Vascular niche

Indexed keywords

BONE MARROW; HUMAN; MULTIPLE MYELOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REVIEW; VASCULARIZATION;

BONE MARROW; HUMANS; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84897455945     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4209     Document Type: Review

References (72)

1. Li, L. and Xie, T. Stem cell niche: structure and function. Ann Rev Cell Dev Biol 21:605-631; (2005)
2. Scadden, D. T. The stem-cell niche as an entity of action. Nature 441:1075-1079; (2006)
3. Krause, D. S. Regulation of hematopoietic stem cell fate. Oncogene 21:3262-3269; (2002)
4. Kopp, H. G.; Avecilla, S. T.; Hooper, A. T. and Rafii, S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology 20:349-356; (2005)
5. Wilson, A. and Trumpp, A. Bone marrow haematopoietic-stem-cell niches. Nat Rev Immunol 6:93-106; (2006)
6. Zhang, J.; Niu, C.; Ye, L.; Huang, H.; He, X.; Tong, W. G.; Ross, J.; Haug, J.; Johnson, T.; Feng, J. Q.; Harris, S.; Wiedemann, L. M.; Mishina, Y. and Li, L. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425:836-841; (2003)
7. Calvi, L. M.; Adams, G. B.; Weibrecht, K. W.; Weber, J. M.; Olson, D. P.; Knight, M. C.; Martin, R. P.; Schipani, E.; Divieti, P.; Bringhurst, F. R.; Milner, L. A.; Kronenberg, H. M. and Scadden, D. T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425: 841-846; (2003)
8. Rizo, A.; Vellenga, E.; de Haan, G. and Schuringa, J.J.Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet 15:R210-219; (2006)
9. Koop, H. G.; Avecilla, S. T.; Hooper, A. T. and Rafii, S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology (Bethesda) 20:349-356; (2005)
10. Abkowitz, JL.; Robinson, AE.; Kale, S.; Long, M. W. and Chen, J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. Blood 102:1249-1253; (2003)
11. .Yin, T. and Li, L. The stem cell niches in bone. J Clin Invest 116:1195-1201; (2006)
12. Moore, K. A. and Lemischka, I. R. Stem cells and their niches. Science 311:1880-1885; (2006)
13. Li, L. and Neaves, W. B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 66:4553-4557; (2006)
14. Perry, J. M. and Li, L. Distrupting the stem cell niche: good seeds in bad soil. Cell 129:1045-1047; (2007)
15. Carlesso, N. and Cardoso, A. A. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol 17: 281-286; (2010)
16. Raaijmakers, M. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica 96:1041-1048; (2011)
17. Butler, J. B.; Kobayashi, H. and Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10:138- 146; (2010)
18. Eliasson, P. and Jonsson, J. L. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 222:17-22; (2010)
19. Abe, M. Targeting the interplay between myeloma cells and the bone marrow microenvriornment in myeloma. Int J Hematol 94:334-343; (2011)
20. Ribatti, D.; Nico, B. and Vacca, A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 25:4257-4266; (2006)
21. Nyangoga, H.; Mercier, P.; Libouban, H.; Baslè, M. F. and Chappard, D. Three-dimensional characterization of the vascular bed in bone metastasis of the rat by microcomputed tomography (Micro CT). PLoS One 6:e17366; (2011)
22. Vacca, A. and Ribatti, D. Bone marrow angiogenesis in multiple myeloma. Leukemia 20:193-199; (2006)
23. Vacca, A. and Ribatti, D. Angiogenesis and vasculogenesis in multiple myeloma: role of inflammatory cells. Recent Results Cancer Res 183:87-95; (2011)
24. Ria, R.; Piccoli, C.; Cirulli, T.; Falzetti, F.; Mangialardi, G.; Guidolin, D.; Tabilio, A.; Di Renzo, N.; Guarini, A.; Ribatti, D; Dammacco, F. and Vacca, A. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma. Clin Cancer Res 14:1678-1685; (2008)
25. Bataille, R.; Chappard, D.; Marcelli, C.; Dessauw, P.; Sany, J.; Baldet, P. and Alexandre, C. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 7:1904-1914; (1989)
26. Terpos, E. and Dimopoulos, M. A. Myeloma bone disease: pathophysiology and management. Ann Oncol 16:1223-1231; (2005)
27. Croucher, P. I.; De Hendrik, R.; Perry, M. J.; Hijzen, A.; Schipman, C. M.; Lippitt, J.; Green, J.; Van Marck, E.; Van Camp, B. and Vanderkerken, K. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis and increased survival. J Bone Miner Res 18:482-492; (2003)
28. Tanaka, Y.; Abe, M.; Hiasa, M.; Oda, A.; Amou, H.; Nakano, A.; Takeuchi, K.; Kitazoe, K.; Kido, S.; Inoue, D.; Moriyama, K.; Hashimoto, T.; Ozaki, S. and Matsumoto, T. Myeloma cell-osteoclasts interaction enhances angiogenesis together with bone resorption: a role foe vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13:816-823; (2007)
29. Abe, M.; Hiura, K.; Wilde, J.; Shioyasono, A.; Moriyama, K.; Hashimoto, T.; Kido, S.; Oshima, T.; Shibata, H.; Ozaki, S.; Inoue, D. and Matsumoto, T. Osteoclasts enhaonce myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104:2484-2491; (2004)
30. Asou, Y.; Rittling, S. R.; Yoshitake, H.; Tsuji, K.; Shinomiya, K.; Nifuji, A.; Denhardt, D. T. and Noda, M. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142:1325-1332; (2001)
31. Cackowski, F. C.; Anderson, J. L.; Patrene, K. D.; Choksi, R. J.; Shapiro, S. D.; Windle, J. J.; Blair, H. C. and Roodman, G. D. Osteoclasts are important for bone angiogenesis. Blood 115:140-149; (2009)
32. Vande Broek, I.; Asosingh, K.; Allegaert, V.; Leleu, X.; Facon, T.; Vanderkerken, K.; Van Camp, B. and Van Riet, I. Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor. Leukemia 18:976-982; (2004)
33. .Alexandrakis, M. G.; Passam, F. H.; Boula, A.; Christophoridou, A.; Aloizos, G.; Roussou, P. and Kyriakou, D. S. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 82:19-23; (2003)
34. Cohen, T.; Nahari, D.; Cerem, L. W.; Neufeld, G. and Levi, B. Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-741; (1996)
35. Yaccoby, S.; Wezeman, M.J.; Henderson, A.; Cottler-Fox, M.; Yi, Q.; Barlogie, B. and Epstein, J. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64:2016-2023; (2004)
36. Novak, A. J.; Darce, J. R.; Arendt, B. K.; Harder, B.; Henderson, K.; Kindsvogel, W.; Gross, J. A.; Greipp, P. R. and Jelinek, D. F. Expression of BMCA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689-694; (2004)
37. Okano, A.; Suzuki, C.; Takatsuki, F.; Akiyama, Y.; Koike, K.; Nakahata, T.; Hirano, T.; Kishimoto, T.; Ozawa, K. and Asano, S. Effects of interleukin-6 on hematopoiesis in bone marrow-transplanted mice. Transplantation 47:738-740; (1989)
38. Kawano, M. M.; Mihara, K.; Huang, N.; Tsujimoto, T. and Kuramoto, A. Differentiation of early plasma cells on bone marrow stromal cells requires interleukin- 6 for escaping from apoptosis. Blood 85:487-494; (1995)
39. .Martin, S. K.; Diamond, P.; Gronthos, S.; Peet, D. J. and Zannettino, A. C. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 25:1533-1542; (2011)
40. Martin, S. K.; Diamond, P.; Williams, S. A.; To, L. B.; Peet, D. J.; Fujii, N.; Gronthos, S.; Harris, A. L. and Zannettino, A. C. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 95:776-784; (2010)
41. Pellegrino, A.; Ria, R.; Di Pietro, G.; Cirulli, T.; Surico, G.; Pennisi, A.; Morabito, F.; Ribatti, D. and Vacca, A. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol 129:248-256; (2005)
42. Arai, F.; Hirao, A.; Ohmura, M.; Sato, H.; Matsuoka, S.; Takubo, K.; Ito, K.; Koh, G. Y. and Suda, T. Tie2/angiopietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 118:149-161; (2004)
43. .Giuliani, N.; Colla, S.; Lazzaretti, M.; Sala, R.; Roti, G.; Mancini, C.; Bonomini, S.; Lunghi, P.; Hojden, M.; Genestreti, G.; Svaldi, M.; Coser, P.; Fattori, P. P.; Sammarelli, G.; Gazzola, G. C.; Bataille, R.; Almici, C.; Caramatti, C.; Mangoni, L. and Rizzoli, V. Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102:638-645; (2003)
44. .Ribatti, D. and Vacca, A. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19:1525-1531; (2005)
45. Davies, F. E.; Raje, N.; Hideshima, T.; Lentzsch, S.; Young, G.; Tai, Y. T.; Lin, B.; Podar, K.; Gupta, D.; Chauhan, D.; Treon, S. P.; Richardson, P. G.; Schlossman, R. L.; Morgan, G. J.; Muller, G. W.; Stirling, D. I. and Anderson, K. C. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98:210-216; (2001)
46. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Chauhan, D.; Richardson, P. G.; Hideshima, T.; Munshi, N. C.; Treon, S. P. and Anderson, K. C. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99:4525-4530; (2002)
47. .Lu, L.; Payvandi, F.; Wu, L.; Zhang, L. H.; Hariri, R. J.; Man, H. W.; Chen, R. S.; Muller, G. W.; Hughes, C. C.; Stirling, D. I.; Schafer, P. H. and Bartlett, J. B. The anticancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 77:78-86; (2009)
48. Dredge, K.; Horsfall, R.; Robinson, S. P.; Zhang, L. H.; Lu, L.; Tang, Y.; Shirley, M. A.; Muller, G.; Schafer, P.; Stirling, D.; Dalgleish, A. G. and Bartlett, J. B. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69: 56-63; (2005)
49. Chang, D. H.; Liu, N.; Klimek, V.; Hassoun, H.; Mazumder, A.; Nimer, S. D.; Jagannath, S. and Dhodapkar, M. V. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108:618-621; (2006)
50. Hideshima, T.; Mitsiades, C.; Tonon, G.; Richardson, P. G. and Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 8:585-598; (2007)
51. Görgün, G.; Calabrese, E.; Soydan, E.; Hideshima, T.; Perrone, G.; Bandi, M.; Cirstea, D.; Santo, L.; Hu, Y.; Tai, Y. T.; Nahar, S.; Mimura, N.; Fabre, C.; Raje, N.; Munshi, N.; Richardson, P. and Anderson, K. C. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 116:3227-3237; (2010)
52. Anderson, G.; Gries, M.; Kurihara, N.; Honio, T.; Anderson, J.; Donnenberg, V.; Donnenberg, A.; Ghobrial, I.; Mapara, M. Y.; Stirling, D.; Roodman, D. and Lentzsch, S. Thalidomide derivative CC-4047 inhibits osteoclast formation by downregulation of PU.1. Blood 107:3098-3105; (2006)
53. Breitkreutz, I.; Raab, M. S.; Vallet, S.; Hideshima, T.; Raje, N.; Mitsiades, C.; Chauhan, D.; Okawa, Y.; Munshi, N. C.; Richardson, P. G. and Anderson, K. C. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22:1925-1932; (2008)
54. Wang, M.; Dimopoulos, M. A.; Chen, C.; Cibeira, M. T.; Attal, M.; Spencer, A.; Rajkumar, S. V.; Yu, Z.; Olesnyckyj, M.; Zeldis, J. B.; Knight, R. D. and Weber, D. M. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 112:4445-4451; (2008)
55. Dimopoulos, M.; Spencer, A.; Attal, M.; Prince, H. M.; Harousseau, J. L.; Dmoszynska, A.; San Miguel, J.; Hellmann, A.; Facon, T.; Foa, R.; Corso, A.; Masliak, Z.; Olesnyckyj, M.; Yu, Z.; Patin, J.; Zeldis, J. B. and Knight, R. D. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132; (2007)
56. Weber, D. M.; Chen, C.; Niesvizky, R.; Wang, M.; Belch, A.; Stadtmauer, E. A.; Siegel, D.; Borrello, I.; Rajkumar, S. V.; Chanan-Khan, A. A.; Lonial, S.; Yu, Z.; Patin, J.; Olesnyckyj, M.; Zeldis, J. B. and Knight, R. D. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142; (2007)
57. Kastritis, E.; Palumbo, A. and Dimopoulos, M. A. Treatment of relapsed/refractory multiple myeloma. Semin Hematol 46:143-157; (2009)
58. Dimopoulos, M.A.; Kastritis, E.; Christoulas, D.; Migkpu, M.; Gavriatipoulou, M.; Gkotzamanidou, M.; Iakovaki, M.; Matsouka, C.; Mparmparoussi, D.; Roussou, M.; Efstathiou, E. and Rerpos, E. Treatment of patients with relpased/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenic abnormalities and of previous therapies. Leukemia 24:1769-1778; (2010)
59. Barosi, G.; Merlini, G.; Billio, A.; Boccadoro, M.; Corradini, P.; Marchetti, M.; Massaia, M.; Tosi, P.; Palumbo, A.; Cavo, M. and Tura, S. SIE, SIES, GIT MO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Ann Hematol 91:875-888; (2012)
60. Williams, S.; Pettaway, C.; Song, R.; Papandreou, C.; Logothetis, C. and McConkey, D. J. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2:835-843; (2003)
61. Roccaro, A. M.; Hideshima, T.; Raje, N.; Kumar, S.; Ishitsuka, K.; Yasui, H.; Shiraishi, N.; Ribatti, D.; Nico, B.; Vacca, A.; Dammacco, F.; Richardson, P. G. and Anderson, K. C. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66:184-191; (2006)
62. Hideshima, T.; Chauhan, D.; Hayashi, T.; Akiyama, M.; Mitsiades, N.; Mitsiades, C.; Podar, K.; Munshi, N. C.; Richardson, P. G. and Anderson, K. C. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22:8386-8393; (2003)
63. Shin, D. H.; Chun, Y. S.; Lee, D. S.; Huang, L. E. and Park, J. W. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111:3131-3136; (2008)
64. Hideshima, T.; Chauhan, D.; Richardson, P.; Mitsiades, C.; Mitsiades, N.; Hayashi, T.; Munshi, N.; Dang, L.; Castro, A.; Palombella, V.; Adams, J. and Anderson, K. C. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647; (2002)
65. Rajkumar, S. V. and Sonneveld, P. Front-line treatment in younger patients with multiple myeloma. Semin Hematol 46:118-126; (2009)
66. Moschetta, M.; Di Pietro, G.; Ria, R.; Gnoni, A.; Mangialardi, G.; Guarini, A.; Ditonno, P.; Musto, P.; D'Auria, F.; Ricciardi, M. R.; Dammacco, F.; Ribatti, D. and Vacca, A. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. Eur J Cancer 46:420-429; (2010)
67. Lund, T.; Soe, K.; Abidgaard, N.; Garnero, P.; Pedersen, P. T.; Ormstrup, T.; Delaissé, J. M. and Plesner, T. Firstline treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol 85:290-292; (2010)
68. Mukhejee, S.; Raje, N.; Schoonmaker, J. A.; Liu, J. C.; Hideshima, T.; Wein, M. N.; Jones, D. C.; Vallet, S.; Bouxsein, M. L.; Pozzi, S.; Chherti, S.; Seo, Y. D.; Aronson, J. P.; Patel, C.; Fulciniti, M.; Purton, L. E.; Glimcher, L. H.; Lian, J. B.; Stein, G.; Anderson, K. C. and Scadden, D. T. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 118:491-504; (2008)
69. Chauhan, D.; Hideshima, T. and Anderson, K. C. Targeting proteasome as therapy in multiple myeloma. Adv Exp Med Biol 615:251-260; (2008)
70. Scavelli, C.; Di Pietro, G.; Cirulli, T.; Coluccia, M.; Boccarelli, A.; Giannini, T.; Mangialardi, G.; Bertieri, R.; Coluccia, A. M.; Ribatti, D.; Dammacco, F. and Vacca, A. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 6:3256-3262; (2007)
71. Henk, H.J.; Teitelbaum A.; Perez, J.R. and Kaura, S. Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma. Am J Hematol 87:490-495; (2012)
72. Morgan, G.J.; Davies, F.E.; Gregory, W.M.; Szubert A.J.; Bell, S.E.; Drayson, M.T.; Owen, R.G.; Ashcroft, A.J.; Jackson, G.H. and Child, J.A. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood 119:5374-5383; (2012)